It’s a Monday morning in late March, and Dan Doctoroff is explaining how he’ll die from ALS. “Respiratory failure,” he says calmly, without breaking eye contact, from his home in New York.

A potential new treatment for neurological disease ALS has shown promising results after being tested on its first patient ALS is notoriously difficult to treat, with most patients dying three to five ...

Ractigen Therapeutics, a clinical-stage Pharmaceutical company dedicated to developing RNA-based innovative therapies, today announced the successful dosing of the first patient in the Phase I ...